687 related articles for article (PubMed ID: 28724365)
1. Leflunomide is equally efficacious and safe compared to low dose rituximab in refractory rheumatoid arthritis given in combination with methotrexate: results from a randomized double blind controlled clinical trial.
Wijesinghe H; Galappatthy P; de Silva R; Seneviratne SL; Saravanamuttu U; Udagama P; Hart M; Kelleher P; Senerath U; Fernandopulle R; Weerasekera LP; Wijayaratne LS
BMC Musculoskelet Disord; 2017 Jul; 18(1):310. PubMed ID: 28724365
[TBL] [Abstract][Full Text] [Related]
2. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial.
Emery P; Fleischmann R; Filipowicz-Sosnowska A; Schechtman J; Szczepanski L; Kavanaugh A; Racewicz AJ; van Vollenhoven RF; Li NF; Agarwal S; Hessey EW; Shaw TM;
Arthritis Rheum; 2006 May; 54(5):1390-400. PubMed ID: 16649186
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of leflunomide 100mg weekly compared to low dose methotrexate in patients with active rheumatoid arthritis. Double blind, randomized clinical trial.
Jaimes-Hernández J; Meléndez-Mercado CI; Mendoza-Fuentes A; Aranda-Pereira P; Castañeda-Hernández G
Reumatol Clin; 2012; 8(5):243-9. PubMed ID: 22763150
[TBL] [Abstract][Full Text] [Related]
4. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group.
Cohen S; Cannon GW; Schiff M; Weaver A; Fox R; Olsen N; Furst D; Sharp J; Moreland L; Caldwell J; Kaine J; Strand V
Arthritis Rheum; 2001 Sep; 44(9):1984-92. PubMed ID: 11592358
[TBL] [Abstract][Full Text] [Related]
5. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial.
Kremer JM; Genovese MC; Cannon GW; Caldwell JR; Cush JJ; Furst DE; Luggen ME; Keystone E; Weisman MH; Bensen WM; Kaine JL; Ruderman EM; Coleman P; Curtis DL; Kopp EJ; Kantor SM; Waltuck J; Lindsley HB; Markenson JA; Strand V; Crawford B; Fernando I; Simpson K; Bathon JM
Ann Intern Med; 2002 Nov; 137(9):726-33. PubMed ID: 12416946
[TBL] [Abstract][Full Text] [Related]
6. Comparison of combination therapy with methotrexate and sinomenine or leflunomide for active rheumatoid arthritis: A randomized controlled clinical trial.
Huang RY; Pan HD; Wu JQ; Zhou H; Li ZG; Qiu P; Zhou YY; Chen XM; Xie ZX; Xiao Y; Huang QC; Liu L
Phytomedicine; 2019 Apr; 57():403-410. PubMed ID: 30851515
[TBL] [Abstract][Full Text] [Related]
7. Preliminary evaluation in rheumatoid arthritis activity in patients treated with TNF-alpha blocker plus methotrexate versus methotrexate or leflunomide alone.
Wisłowska M; Jakubicz D
Rheumatol Int; 2007 May; 27(7):641-7. PubMed ID: 17235556
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of an anti-CD20 monoclonal antibody (Reditux™) for the treatment of patients with moderate to severe rheumatoid arthritis following the failure of conventional synthetic disease-modifying anti-rheumatic drugs.
Bhati M; Bandyopadhyay S
Clin Rheumatol; 2016 Aug; 35(8):1931-1935. PubMed ID: 27334114
[TBL] [Abstract][Full Text] [Related]
9. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
Cohen SB; Emery P; Greenwald MW; Dougados M; Furie RA; Genovese MC; Keystone EC; Loveless JE; Burmester GR; Cravets MW; Hessey EW; Shaw T; Totoritis MC;
Arthritis Rheum; 2006 Sep; 54(9):2793-806. PubMed ID: 16947627
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial.
Greenwald MW; Shergy WJ; Kaine JL; Sweetser MT; Gilder K; Linnik MD
Arthritis Rheum; 2011 Mar; 63(3):622-32. PubMed ID: 21360491
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration.
Chatzidionysiou K; Lie E; Nasonov E; Lukina G; Hetland ML; Tarp U; van Riel PL; Nordström DC; Gomez-Reino J; Pavelka K; Tomsic M; Kvien TK; van Vollenhoven RF; Gabay C
Ann Rheum Dis; 2012 Mar; 71(3):374-7. PubMed ID: 21972242
[TBL] [Abstract][Full Text] [Related]
12. Leflunomide in monotherapy of rheumatoid arthritis: meta-analysis of randomized trials.
Golicki D; Newada M; Lis J; Pol K; Hermanowski T; Tłustochowicz M
Pol Arch Med Wewn; 2012; 122(1-2):22-32. PubMed ID: 22353705
[TBL] [Abstract][Full Text] [Related]
13. Leflunomide in the treatment of rheumatoid arthritis.
Li EK; Tam LS; Tomlinson B
Clin Ther; 2004 Apr; 26(4):447-59. PubMed ID: 15189743
[TBL] [Abstract][Full Text] [Related]
14. Comparative assessment of leflunomide and methotrexate for the treatment of rheumatoid arthritis, by dynamic enhanced magnetic resonance imaging.
Reece RJ; Kraan MC; Radjenovic A; Veale DJ; O'Connor PJ; Ridgway JP; Gibbon WW; Breedveld FC; Tak PP; Emery P
Arthritis Rheum; 2002 Feb; 46(2):366-72. PubMed ID: 11840438
[TBL] [Abstract][Full Text] [Related]
15. Leflunomide or methotrexate? Comparison of clinical efficacy and safety in low socio-economic rheumatoid arthritis patients.
Ishaq M; Muhammad JS; Hameed K; Mirza AI
Mod Rheumatol; 2011 Aug; 21(4):375-80. PubMed ID: 21229373
[TBL] [Abstract][Full Text] [Related]
16. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of atacicept in combination with rituximab for reducing the signs and symptoms of rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled pilot trial.
van Vollenhoven RF; Wax S; Li Y; Tak PP
Arthritis Rheumatol; 2015 Nov; 67(11):2828-36. PubMed ID: 26137975
[TBL] [Abstract][Full Text] [Related]
18. A 48-week, randomized, double-blind, double-observer, placebo-controlled multicenter trial of combination methotrexate and intramuscular gold therapy in rheumatoid arthritis: results of the METGO study.
Lehman AJ; Esdaile JM; Klinkhoff AV; Grant E; Fitzgerald A; Canvin J;
Arthritis Rheum; 2005 May; 52(5):1360-70. PubMed ID: 15880810
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.
Genovese MC; Fleischmann R; Combe B; Hall S; Rubbert-Roth A; Zhang Y; Zhou Y; Mohamed MF; Meerwein S; Pangan AL
Lancet; 2018 Jun; 391(10139):2513-2524. PubMed ID: 29908670
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study.
Aletaha D; Bingham CO; Tanaka Y; Agarwal P; Kurrasch R; Tak PP; Popik S
Lancet; 2017 Mar; 389(10075):1206-1217. PubMed ID: 28215362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
